Skip to main content
Clinical Trials/ISRCTN37913976
ISRCTN37913976
Completed
未知

A feasibility study to inform the design of a randomised controlled trial to identify the most clinically and cost effective length of anticoagulation with low molecular weight heparin In the treatment of Cancer Associated Thrombosis

Cardiff University (UK)0 sites200 target enrollmentOctober 31, 2012

Overview

Phase
未知
Intervention
Not specified
Conditions
Not specified
Sponsor
Cardiff University (UK)
Enrollment
200
Status
Completed
Last Updated
6 years ago

Overview

Brief Summary

Registry
who.int
Start Date
October 31, 2012
End Date
November 22, 2014
Last Updated
6 years ago
Study Type
Interventional
Sex
All

Investigators

Sponsor
Cardiff University (UK)

Eligibility Criteria

Inclusion Criteria

  • 1\. Receiving low\-molecular\-weight heparin (LMWH) for treatment of Cancer Associated Thrombosis (CAT) for five months
  • 2\. Locally advanced or metastatic cancer
  • 3\. Able to self\-administer LMWH, or have LMWH administered by a carer
  • 4\. Able to give informed consent
  • 5\. Age \=18 years

Exclusion Criteria

  • 1\. Receiving drug other than LMWH for CAT
  • 2\. Contraindication to anticoagulation
  • 2\.1\. Known allergies to LMWHs, heparin, sulfites or benzyl alcohol
  • 2\.2\. Active major bleeding
  • 2\.3\. History of heparin\-induced thrombocytopenia
  • 3\. Confirmed recurrent VTE whilst receiving anticoagulation
  • 4\. Female patients who are pregnant

Outcomes

Primary Outcomes

Not specified

Similar Trials